Learn how Signatera, a breakthrough technology, can be applied in early stage and late stage cancer trials.
| This week's Fierce LifeSci is brought to you by Natera.
Trouble viewing? Click here. |
| Date: Tuesday, October 27, 2020 Time: 4pm ET / 1pm PT Duration: 1 Hour |
|
| Discover the latest advantages of using a personalized, tumor-informed circulating tumor DNA (ctDNA) test to design oncology clinical trials in solid tumors, and Breast Cancer in particular. Presentation topics will include: Latest data in Breast Cancer from 2020 publications and abstracts Advantages of a personalized, tumor-informed ctDNA assay for molecular residual disease detection Signatera clinical data in early and late stage Breast Cancer Applications of Signatera in clinical trial design to maximize trial success, and accelerate time to data readout Register Now |
|
|
| You are currently subscribed as newsletter@newslettercollector.com
If you no longer wish to receive promotions from Fierce LifeSciences, simply unsubscribe.
Refer to our Privacy Policy.
Fierce LifeSciences is a division of Questex LLC.
685 3rd Ave 21st Floor New York, NY 10017
© 2020 Questex LLC. All Rights Reserved.
Reproduction in whole or in part is prohibited without written permission. |
|
